专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070140981A1 Intranasal compositions 失效
标题翻译：鼻内成分
公开(公告)号：US20070140981A1
公开(公告)日：2007-06-21
申请号：US10596817
申请日：2004-12-23
申请人： Jonathan Castile , Yu-Hui Cheng , Paul Jenkins , Alan Smith , Peter Watts
发明人： Jonathan Castile , Yu-Hui Cheng , Paul Jenkins , Alan Smith , Peter Watts
IPC分类号： A61K9/14 , A61K31/4745
CPC分类号： B82Y5/00 , A61K9/0043 , A61K9/1623 , A61K9/1652 , A61K31/4184 , A61K47/36 , A61K47/40 , A61K47/6951 , Y10S514/923
摘要： The present invention provides compositions for the intranasal administration of zolpidem or a pharmaceutically acceptable salt thereof. Preferred compositions of the invention are in the form of aqueous solutions. Optionally the compositions of the invention comprise a cyclodextrin and/or chitosan, a salt or derivative thereof or a salt of a derivative of chitosan. The compositions can be used for the treatment or prevention insomnia or the treatment of neurological disorders such as those arising from brain trauma, stroke and spinocerebellar ataxia or in the treatment of Parkinson's disease.
摘要翻译：本发明提供了用于鼻内施用唑吡旦或其药学上可接受的盐的组合物。本发明的优选组合物是水溶液的形式。任选地，本发明的组合物包含环糊精和/或壳聚糖，其盐或衍生物或壳聚糖衍生物的盐。该组合物可用于治疗或预防失眠或治疗诸如由脑创伤，中风和脊髓小脑共济失调引起的神经障碍或治疗帕金森病。

2. 发明申请

US20050142073A1 Intranasal compositions 有权
标题翻译：鼻内成分
公开(公告)号：US20050142073A1
公开(公告)日：2005-06-30
申请号：US11004556
申请日：2004-12-03
申请人： Peter Watts , Alan Smith , Jonathan Castile
发明人： Peter Watts , Alan Smith , Jonathan Castile
IPC分类号： A61K9/00 , A61K31/435 , A61K47/36 , A61K31/46 , A61K9/14 , A61L9/04
CPC分类号： A61K9/0043 , A61K31/435
摘要： Compositions are provided for the intranasal administration of granisetron or a pharmaceutically acceptable salt thereof. Preferred compositions are in the form of an aqueous solution. Optionally, the compositions comprise chitosan, a salt or derivative thereof or a salt of a derivative of chitosan. The compositions can be used for the treatment or prevention of nausea and/or vomiting.
摘要翻译：提供了用于格拉司琼或其药学上可接受的盐的鼻内给药的组合物。优选的组合物是水溶液的形式。任选地，组合物包含壳聚糖，其盐或衍生物或壳聚糖衍生物的盐。该组合物可用于治疗或预防恶心和/或呕吐。

3. 发明申请

US20110257632A1 DEVICE FOR ADMINISTERING LIQUID ANALGESICS 审中-公开
标题翻译：用于管理液体药物的装置
公开(公告)号：US20110257632A1
公开(公告)日：2011-10-20
申请号：US13122332
申请日：2009-09-28
申请人： Jonathan Castile , Peter Watts , Alan Smith
发明人： Jonathan Castile , Peter Watts , Alan Smith
IPC分类号： A61M1/00
CPC分类号： A61M15/08 , A61M15/0073
摘要： In the field of pain relief and treatment there is a need for a device which is able to administer several predetermined doses of an opioid analgesic in a manner which can be done simply and safely by a patient or carer; in particular in a manner which minimises the risk of administering too great a dose at any one time. A device (10), for administering a predefined number (N) of predefined volume unit doses (Vu) of an opioid analgesic in liquid form, includes a closed container (12) which contains a predetermined fill volume (Vf) of the opioid analgesic, and a dispenser (14) that is connected to the container (12). The dispenser (14) is operable to administer an individual one volume unit dose (Vu) repeatedly said predefined number of times (N). Both the dispenser (14) is adapted, and the concentration of said opioid analgesic is chosen such that said volume unit dose is in the range 0.05 to 0.15 ml.
摘要翻译：在疼痛缓解和治疗领域中，需要能够以可由患者或护理人员简单且安全地进行的方式施用若干预定剂量的阿片类止痛剂的装置; 特别是以任何时候最小化施用过大剂量的风险的方式。用于施用液体形式的阿片样镇痛剂的预定数量（N）预定体积单位剂量（Vu）的装置（10）包括封闭容器（12），其包含所述阿片样镇痛药的预定填充体积（Vf）以及连接到容器（12）的分配器（14）。分配器（14）可操作以重复地施加单独的一个体积单位剂量（Vu）所述预定次数（N）。适配分配器（14），并且选择所述阿片样镇痛剂的浓度使得所述体积单位剂量在0.05至0.15ml的范围内。

4. 发明申请

US20060120973A1 Pharmaceutical formulations for intranasal administration of protein comprising a chitosan or a derivative thereof 失效
公开(公告)号：US20060120973A1
公开(公告)日：2006-06-08
申请号：US11325073
申请日：2006-01-04
申请人： Ann Dyer , Peter Watts , Yu-Hui Cheng , Alan Smith
发明人： Ann Dyer , Peter Watts , Yu-Hui Cheng , Alan Smith
IPC分类号： A61K38/17 , A61K31/722 , A61L9/04 , A61K9/14
CPC分类号： A61K9/0043 , A61K9/1652 , A61K38/27 , A61K47/36 , Y10S514/951
摘要： There is provided a powder formulation for nasal delivery including a protein having a molecular weight of 10 kDa or greater and chitosan or a derivative thereof or a salt of chitosan or a salt of a derivative of chitosan. Preferably the protein is human growth hormone.

5. 发明申请

US20070231269A1 Analgesics 审中-公开
标题翻译：止痛药
公开(公告)号：US20070231269A1
公开(公告)日：2007-10-04
申请号：US11798384
申请日：2007-05-14
申请人： Phillip Birch , Ann Hayes , Peter Watts , Jonathan Castile
发明人： Phillip Birch , Ann Hayes , Peter Watts , Jonathan Castile
IPC分类号： A61K9/00 , A61K47/34 , A61K47/36 , A61K47/38
CPC分类号： A61K31/407 , A61K9/0043 , A61K31/195 , A61K31/196 , A61K31/405 , A61K31/485 , A61K31/54 , A61K31/5415 , A61K47/34 , A61K47/36 , A61K47/38
摘要： An analgesic and a delivery agent are combined in a pharmaceutical composition such that, on introduction into the nasal cavity of a patient to be treated, the analgesic may be delivered to the bloodstream to produce within 30 minutes a therapeutic plasma concentration, Cther, of 0.2 ng/ml or greater which is maintained for a duration Tmaint of at least 2 hours. The analgesic may be an opioid analgesic or a non-steroidal anti-inflammatory drug.
摘要翻译：镇痛剂和递送剂组合在药物组合物中，使得在引入待治疗的患者的鼻腔中时，止痛剂可以在30分钟内递送到血流中以在治疗血浆浓度C < 其为0.2ng / ml或更大，其维持持续时间为至少2小时。止痛剂可以是阿片样镇痛药或非甾体抗炎药。

6. 发明申请

US20050142072A1 Analgesics for nasal administration 审中-公开
标题翻译：鼻腔给药止痛药
公开(公告)号：US20050142072A1
公开(公告)日：2005-06-30
申请号：US10508315
申请日：2003-03-19
申请人： Phillip Birch , Ann Hayes , Peter Watts , Jonathan Castile
发明人： Phillip Birch , Ann Hayes , Peter Watts , Jonathan Castile
IPC分类号： A61K9/08 , A61K9/00 , A61K9/12 , A61K31/195 , A61K31/196 , A61K31/405 , A61K31/407 , A61K31/485 , A61K31/54 , A61K31/5415 , A61K45/00 , A61K47/02 , A61K47/10 , A61K47/14 , A61K47/18 , A61K47/26 , A61K47/34 , A61K47/36 , A61K47/38 , A61M11/00 , A61M15/08 , A61P5/24 , A61P15/00 , A61P25/02 , A61P25/04 , A61P27/16 , A61P29/00 , A61P43/00 , A61L9/04 , A61K9/14
CPC分类号： A61K31/407 , A61K9/0043 , A61K31/195 , A61K31/196 , A61K31/405 , A61K31/485 , A61K31/54 , A61K31/5415 , A61K47/34 , A61K47/36 , A61K47/38
摘要： An analgesic and a delivery agent are combined in a pharmaceutical composition such that, on introduction into the nasal cavity of a patient to be treated, the analgesic may be delivered to the bloodstream to produce within 30 minutes a therapeutic plasma concentration, Cther, of 0.2 ng/ml or greater which is maintained for a duration Tmaint of at least 2 hours. The analgesic may be an opioid analgesic or a non-steroidal anti-inflammatory drug.
摘要翻译：镇痛剂和递送剂组合在药物组合物中，使得在引入待治疗的患者的鼻腔中时，止痛剂可以在30分钟内递送到血流中以在治疗血浆浓度C < 其为0.2ng / ml或更大，其维持持续时间为至少2小时。止痛剂可以是阿片样镇痛药或非甾体抗炎药。

7. 发明申请

US20050085440A1 Formulation 失效
标题翻译：公式
公开(公告)号：US20050085440A1
公开(公告)日：2005-04-21
申请号：US10508336
申请日：2002-03-19
申请人： Philip Birch , Ann Hayes , Peter Watts , Jonathan Castile
发明人： Philip Birch , Ann Hayes , Peter Watts , Jonathan Castile
IPC分类号： A61K9/08 , A61K9/00 , A61K9/12 , A61K31/195 , A61K31/196 , A61K31/405 , A61K31/407 , A61K31/485 , A61K31/54 , A61K31/5415 , A61K45/00 , A61K47/02 , A61K47/10 , A61K47/14 , A61K47/18 , A61K47/26 , A61K47/34 , A61K47/36 , A61K47/38 , A61M11/00 , A61M15/08 , A61P5/24 , A61P15/00 , A61P25/02 , A61P25/04 , A61P27/16 , A61P29/00 , A61P43/00 , A61K31/732
CPC分类号： A61K31/407 , A61K9/0043 , A61K31/195 , A61K31/196 , A61K31/405 , A61K31/485 , A61K31/54 , A61K31/5415 , A61K47/34 , A61K47/36 , A61K47/38
摘要： Aqueous formulations suitable for intranasal administration comprise buprenorphine or a physiologically acceptable salt or ester thereof and (a) a pectin having a degree of esterification of less than 50%, (b) chitosan and a polyoxyethylene-polyoxypropylene copolymer (poloxamer) or (c) chitosan and hydroxypropylmethylcellulose. Such formulations can induce rapid and prolonged analgesia when delivered intranasally to a patient. The buprenorphine or buprenorphine salt or ester may be delivered to the bloodstream to produce within 30 minutes a therapeutic plasma concentration of buprenorphine, Cther, of 0.2 ng/ml or greater which is maintained for a duration Tmaint of at least 2 hours.
摘要翻译：适用于鼻内给药的水性制剂包括丁丙诺啡或其生理上可接受的盐或酯，和（a）酯化度小于50％的果胶，（b）壳聚糖和聚氧乙烯 - 聚氧丙烯共聚物（泊洛沙姆）或（c）壳聚糖和羟丙基甲基纤维素。当向患者鼻内递送时，这样的制剂可以诱导快速和延长的止痛。可将丁丙诺啡或丁丙诺啡盐或酯递送至血流，在30分钟内产生治疗血浆浓度为0.2ng / ml或更高的丁丙诺啡，其维持持续时间T < SUB> maint 至少2小时。

8. 发明授权

US08309108B2 Intranasal compositions 有权
标题翻译：鼻内成分
公开(公告)号：US08309108B2
公开(公告)日：2012-11-13
申请号：US12741932
申请日：2008-11-10
申请人： Peter Watts , Yu-Hui Cheng
发明人： Peter Watts , Yu-Hui Cheng
IPC分类号： A61K9/00 , A61P25/16
CPC分类号： A61K31/473 , A61K9/0043 , A61K47/10 , A61K47/36 , A61K47/40
摘要： A liquid aqueous formulation for the intranasal administration of apomorphine includes: (a) at least about 15 mg/ml of apomorphine; and (b) a solubilising agent selected from (i) at least one polyoxyethylene-polyoxypropylene copolymer (poloxamer); (ii) at least one cyclodextrin; and (iii) at least one cyclodextrin together with chitosan. The formulations of the invention can be used in the treatment or management of Parkinson's disease and erectile dysfunction.
摘要翻译：用于鼻内施用阿扑吗啡的液体含水制剂包括：（a）至少约15mg / ml的阿朴吗啡; 和（b）选自（i）至少一种聚氧乙烯 - 聚氧丙烯共聚物（泊洛沙姆）的增溶剂; （ii）至少一种环糊精; 和（iii）至少一种环糊精与壳聚糖一起。本发明的制剂可用于治疗或治疗帕金森病和勃起功能障碍。

9. 发明申请

US20100249170A1 INTRANASAL COMPOSITIONS 有权
标题翻译： INTRANASAL组合物
公开(公告)号：US20100249170A1
公开(公告)日：2010-09-30
申请号：US12741932
申请日：2008-11-10
申请人： Peter Watts , Yu-Hui Cheng
发明人： Peter Watts , Yu-Hui Cheng
IPC分类号： A61K31/473 , A61P25/16 , A61P15/10
CPC分类号： A61K31/473 , A61K9/0043 , A61K47/10 , A61K47/36 , A61K47/40
摘要： A liquid aqueous formulation for the intranasal administration of apomorphine includes: (a) at least about 15 mg/ml of apomorphine; and (b) a solubilising agent selected from (i) at least one polyoxyethylene-polyoxypropylene copolymer (poloxamer); (ii) at least one cyclodextrin; and (iii) at least one cyclodextrin together with chitosan. The formulations of the invention can be used in the treatment or management of Parkinson's disease and erectile dysfunction.
摘要翻译：用于鼻内施用阿扑吗啡的液体含水制剂包括：（a）至少约15mg / ml的阿朴吗啡; 和（b）选自（i）至少一种聚氧乙烯 - 聚氧丙烯共聚物（泊洛沙姆）的增溶剂; （ii）至少一种环糊精; 和（iii）至少一种环糊精与壳聚糖一起。本发明的制剂可用于治疗或治疗帕金森病和勃起功能障碍。

10. 发明授权

US06387917B1 Salts of opioid analgesics, particularly morphine, and methods of using same 有权
标题翻译：阿片类镇痛药，特别是吗啡的盐及其使用方法
公开(公告)号：US06387917B1
公开(公告)日：2002-05-14
申请号：US09692088
申请日：2000-10-19
申请人： Lisbeth Illum , Peter Watts , Ian Lafferty , Alan Smith
发明人： Lisbeth Illum , Peter Watts , Ian Lafferty , Alan Smith
IPC分类号： A61K31485
CPC分类号： C07D489/04
摘要： The methane sulphonate salt of morphine and compositions thereof have medicinal uses, particularly in the treatment of pain. Compositions comprising a methane sulphonate salt of an opioid analgesic also have medicinal uses, adapted for nasal delivery.
摘要翻译：吗啡的甲磺酸盐及其组合物具有药用，特别是用于治疗疼痛。包含阿片类镇痛剂的甲磺酸盐的组合物也具有适于鼻腔输送的药用。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式